$PHAR.AS

Pharming Group reported its Q4 2025 results, showing impressive revenue growth and positive developments in its product pipeline. The call highlighted progress in clinical trials and partnerships, which could enhance market position. However, concerns were raised regarding increased operational costs and competition in the biopharmaceutical sector. The management also provided forward guidance that was slightly below analyst expectations, which may dampen short-term investor sentiment. Overall, the mixed results led to a cautious outlook for the company's stock performance.